Cardiac Cell Therapy Safely Improves Heart Function, Upper Limb Strength in Duchenne Muscular Dystrophy Patients
Phase I/II-A Clinical Trial Results Could Help Lead to Treatment for Fatal, Incurable Disease
Contact: Sally A. Stewart | firstname.lastname@example.org
Ronald G. Victor, MD
Eduardo Marbán, MD, PhD
Los Angeles — Nov. 15, 2017 ─ After boys and young men with Duchenne muscular dystrophy received infusions of cardiac progenitor cells, medical tests indicated that the patients' hearts appeared improved, results from a new study show. Patients in the study also scored higher on arm strength tests after receiving the cell infusions.
Results from the HOPE Duchenne randomized clinical trial of 25 patients were presented today at the American Heart Association Scientific Sessions in Anaheim. The cardiac progenitor cells administered to the patients were contained in CAP-1002, the lead investigational therapy under development at Capricor Therapeutics Inc. (NASDAQ: CAPR).
"This is the first trial to test cell therapy to treat heart disease in patients with Duchenne muscular dystrophy," said Ronald G. Victor, MD, associate director of the Cedars-Sinai Heart Institute and one of the clinical trial's primary investigators. "These early results show that further research is warranted and, in fact, is being planned."
Affecting 1 in 3,600 boys, Duchenne muscular dystrophy is a neuromuscular disease caused by an absence of a key muscle protein called dystrophin, which leads to progressive muscle degeneration. Most Duchenne patients lose their ability to walk between ages 12 and 15. Average life expectancy is about 25 years.
"The need is great because there is no current treatment to address heart failure in these patients," said Eduardo Marbán, MD, PhD, director of the Cedars-Sinai Heart Institute and the researcher who developed the cardiosphere-derived cell (CDC) technology used in the study. "Generally, the primary cause of death in these patients is heart failure. If we can slow or reverse heart failure in Duchenne patients, it will be a step forward."
In the study, 25 patients ages 12 to 22 were treated at the Cedars-Sinai Heart Institute, University of Florida Health or Cincinnati Children's. Twelve patients were randomly assigned to receive standard care consisting of prescription medications. The remaining 13 patients received the standard medications and underwent a minimally invasive procedure during which a catheter was threaded up into each patient's three main coronary arteries before releasing 75 million CDCs grown from donor hearts.
- As measured by MRI, the patients who received the progenitor cells experienced a 7 percent reduction in the area of the heart scarred by cardiomyopathy. Patients who had the usual regimen saw an increase in their heart scars.
- Among the subgroup of patients with the most advanced impairment of arm function, one year after treatment, eight out of nine patients who received the CDCs experienced improved skeletal muscle function in the hands and forearms. Their arm strength was measured by the Performance of the Upper Limb test. The test assesses a patient's ability to perform the arm tasks associated with daily living: arm strength as well as the ability to perform a variety of movements such as picking up coins, removing a container lid and lifting light weights. At that time, none of the patients who received standard medical therapy experienced improved arm strength and function.
- Five of the 13 patients who received cells experienced temporary atrial fibrillation, an irregular and often rapid heart rate that can increase the risk of complications such as stroke and heart failure. Temporary atrial fibrillation is known to occur during cardiac catheterization in patients of this age range.
"We are now planning our Phase II trial, which will be a bit different," Victor said. "Instead of a one-time infusion during a cath lab procedure, the patients will receive the CDCs in an intravenous drip, and will receive multiple treatments spaced over several months."
Pending FDA approval, Victor said, the Phase II trial could begin in early 2018.
Disclosure: The cardiosphere-derived cells used in the Phase I/II HOPE trial were derived from donor hearts and provided by Capricor Therapeutics. Marbán developed the process to grow CDCs when he was on the faculty of Johns Hopkins University; the process was further developed at Cedars-Sinai. Capricor has licensed the process from Johns Hopkins and from Cedars-Sinai for clinical and commercial development. Capricor has licensed additional intellectual property from Cedars-Sinai and the University of Rome. Cedars-Sinai and Marbán have financial interests in Capricor. Victor has been a consultant to the company but was not paid by the company for his work on this study.
The Duchenne muscular dystrophy study was funded in part by a grant from the California Institute for Regenerative Medicine to Capricor. Coalition Duchenne, CureDuchenne and Parent Project Muscular Dystrophy also provided support or guidance.